Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450.

[1]  R. Lemanske,et al.  SAFETY AND ACTIVITY OF SAQUINAVIR IN HIV INFECTION , 1996, Pediatrics.

[2]  R. Colonno,et al.  Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[3]  P. Jadhav,et al.  Stereoselective Synthesis of HIV-1 Protease Inhibitor, DMP 323. , 1996, The Journal of organic chemistry.

[4]  L. M. Lehman,et al.  A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. , 1995, The New England journal of medicine.

[5]  S. Pazhanisamy,et al.  Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. , 1995, The Journal of infectious diseases.

[6]  P. Hsueh,et al.  Decreased activity of erythromycin against Streptococcus pyogenes in Taiwan , 1995, Antimicrobial agents and chemotherapy.

[7]  J. Karn,et al.  Progress in anti-HIV structure-based drug design. , 1995, Trends in biotechnology.

[8]  G. Decrescenzo,et al.  SC-52151, a novel inhibitor of the human immunodeficiency virus protease , 1995, Antimicrobial agents and chemotherapy.

[9]  E D Blair,et al.  Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors , 1995, Antimicrobial agents and chemotherapy.

[10]  J. Lin,et al.  pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[11]  C. Benson,et al.  Viral Dynamics in Human Immunodeficiency Virus Type 1 Infection , 1995 .

[12]  K. Appelt,et al.  Protein structure-based design of potent orally bioavailable, nonpeptide inhibitors of human immunodeficiency virus protease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J. Condra,et al.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.

[14]  L. Bacheler,et al.  Multiple Mutations in the Human Immunodeficiency Virus Protease Gene Are Responsible for Decreased Susceptibility to Protease Inhibitors , 1995 .

[15]  S. Vasavanonda,et al.  ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[16]  D. Ho,et al.  Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor , 1995, Journal of virology.

[17]  J. Coffin,et al.  HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy , 1995, Science.

[18]  A. Perelson,et al.  Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection , 1995, Nature.

[19]  M. Murcko,et al.  Crystal Structure of HIV-1 Protease in Complex with Vx-478, a Potent and Orally Bioavailable Inhibitor of the Enzyme , 1995 .

[20]  N. Roberts.  Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. , 1995, AIDS.

[21]  M. Otto,et al.  Limited sequence diversity of the HIV type 1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors. , 1995, AIDS research and human retroviruses.

[22]  L. Bacheler,et al.  Construction of infectious molecular clones of HIV-1 containing defined mutations in the protease gene. , 1994, Biochemical and biophysical research communications.

[23]  J. Wolff,et al.  Direct gene transfer into muscle. , 1994, Vaccine.

[24]  Charles J. Eyermann,et al.  NMR and X-ray Evidence That the HIV Protease Catalytic Aspartyl Groups Are Protonated in the Complex Formed by the Protease and a Non-Peptide Cyclic Urea-Based Inhibitor , 1994 .

[25]  Y. Wong,et al.  A pharmacokinetic evaluation of HIV protease inhibitors, cyclic ureas, in rats and dogs , 1994, Biopharmaceutics & drug disposition.

[26]  J. Meek,et al.  Potency and selectivity of inhibition of human immunodeficiency virus protease by a small nonpeptide cyclic urea, DMP 323 , 1994, Antimicrobial Agents and Chemotherapy.

[27]  P. Lam,et al.  DMP 323, a nonpeptide cyclic urea inhibitor of human immunodeficiency virus (HIV) protease, specifically and persistently blocks intracellular processing of HIV gag polyprotein , 1994, Antimicrobial Agents and Chemotherapy.

[28]  Dale J. Kempf,et al.  Influence of Stereochemistry on Activity and Binding Modes for C2 Symmetry-Based Diol Inhibitors of HIV-1 Protease , 1994 .

[29]  P. Darke,et al.  L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[30]  P. Jadhav,et al.  An Assay for HIV RNA in Infected Cell Lysates, and its use for the Rapid Evaluation of Antiviral Efficacy , 1994 .

[31]  Ad Bax,et al.  NMR Evidence for the Displacement of a Conserved Interior Water Molecule in HIV Protease by a Non-Peptide Cyclic Urea-Based Inhibitor , 1994 .

[32]  PatrickY.-S. Lam,et al.  Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors. , 1994, Science.

[33]  D. Norbeck,et al.  A C2 symmetry-based HIV protease inhibitor, A77003, irreversibly inhibits infectivity of HIV-1 in vitro. , 1994, AIDS research and human retroviruses.

[34]  A. Skalka,et al.  The retroviral enzymes. , 1994, Annual review of biochemistry.

[35]  P. Lam,et al.  In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor , 1993, Antimicrobial Agents and Chemotherapy.

[36]  P. Jadhav,et al.  In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[37]  K. Appelt,et al.  Crystal structures of HIV-1 protease-inhibitor complexes , 1993 .

[38]  A. Tomasselli,et al.  The crystallographic structure of the protease from human immunodeficiency virus type 2 with two synthetic peptidic transition state analog inhibitors. , 1993, The Journal of biological chemistry.

[39]  V. Johnson,et al.  Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group , 1993, Antimicrobial Agents and Chemotherapy.

[40]  A M Hassell,et al.  A symmetric inhibitor binds HIV-1 protease asymmetrically. , 1993, Biochemistry.

[41]  A. Wlodawer,et al.  Structure-based inhibitors of HIV-1 protease. , 1993, Annual review of biochemistry.

[42]  D. Norbeck,et al.  Stereocontrolled synthesis of C2-symmetric and pseudo-C2-symmetric diamino alcohols and diols for use in HIV protease inhibitors , 1992 .

[43]  Narmada Thanki,et al.  Crystal structure of a complex of HIV‐1 protease with a dihydroxyethylene‐containing inhibitor: Comparisons with molecular modeling , 1992, Protein science : a publication of the Protein Society.

[44]  J. A. Martin,et al.  Recent advances in the design of HIV proteinase inhibitors. , 1992, Antiviral research.

[45]  C. Debouck,et al.  The HIV-1 protease as a therapeutic target for AIDS. , 1992, AIDS research and human retroviruses.

[46]  G. Acsadi,et al.  Conditions affecting direct gene transfer into rodent muscle in vivo. , 1991, BioTechniques.

[47]  D. Norbeck,et al.  Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. , 1990, Science.

[48]  I B Duncan,et al.  Rational design of peptide-based HIV proteinase inhibitors. , 1990, Science.

[49]  A. Konradi,et al.  Intermolecular Pinacol Cross Coupling of Electronically Similar Aldehydes. An Efficient and Stereoselective Synthesis of 1,2-Diols Employing a Practical Vanadium(II) Reagent. , 1990 .

[50]  B. Ho,et al.  Role of human immunodeficiency virus type 1-specific protease in core protein maturation and viral infectivity , 1989, Journal of virology.

[51]  L J Davis,et al.  Active human immunodeficiency virus protease is required for viral infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[52]  B. Honig,et al.  Calculation of the total electrostatic energy of a macromolecular system: Solvation energies, binding energies, and conformational analysis , 1988, Proteins.

[53]  M. Karplus,et al.  Crystallographic R Factor Refinement by Molecular Dynamics , 1987, Science.